D1690R00037
A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03209089/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–100 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 907 чел. во всех странах исследования.
- Плановая дата окончания (04.2019) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 5
Критерии включения
- Age 18 and older;
- Established diagnosis of T2DM (ICD-10 code E11.2-E11.9)
- The current treatment with dapagliflozin prescribed at least 1 month before the FSI;
- Written voluntary informed consent has been provided
- Management in outpatient setting.
Критерии невключения
- Type 1 diabetes
- Current participation in a clinical trial
- Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
- Presence of serious/severe co-morbidities in the opinion of the investigator, which may limit treatment approach as usual.
- Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the 1st Visit
Источник: ClinicalTrials.gov, NCT03209089 · запись обновлена в реестре 1 апреля 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (10)
- Demographic parameters before dapagliflozin initiation in T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- demographic characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- demographic characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
- clinical characteristics of T2DM patients managed by GPs — 3 months before dapagliflozin initiation
Цель исследования
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with type 2 diabetes mellitus (T2DM) initiated with dapagliflozin by general practitioners (GPs) and endocrinologists in real-life setting. It is anticipated that patient recruitment will last 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit. There are 2 time points:
* Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
* Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03209089 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.